Company Alseres Pharmaceuticals, Inc. Other OTC

ALSE

US0211522026

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Diagnostic & Testing Substances Manufacturers

Inactive Instrument

Alseres Pharmaceuticals, Inc. is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS). The Company's lead product candidate is Altropane. The Company's Altropane product is a molecular imaging agent used to diagnose Parkinson's disease and dementia. The Company is focused on entering into partnerships to ensure development and commercialization of its product.

USD in Million	2012	Weight	2013	Weight	Delta
Diagnostic Products 100.0 %	1	100.0 %	0	100.0 %	-10.74%

USD in Million	2012	Weight	2013	Weight	Delta
United States 100.0 %	1	100.0 %	0	100.0 %	-10.74%

Managers	Title	Age	Since
Peter Savas CEO	Chief Executive Officer	75	04-08-31

Members of the board	Title	Age	Since
Peter Savas CEO	Chief Executive Officer	75	04-08-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	12,000	0	0	33.80 %
Stock B	1	6,127	6,127 ( 100.00 %)	0

Name	Equities	%	Valuation
Oppenheim Fonds Trust GmbH 0.0333 %	2	0.0333 %	0 $
Whatifi Asset Management, Inc. 0.000000 %	0	0.000000 %	- $

Name	Equities	%	Valuation
Bob Gipson -	12,000	-	120 $

Alseres Pharmaceuticals, Inc.

275 Grove Street Suite 2-400

02466, Auburndale

+617-419-3289

http://www.alseres.com

address Alseres Pharmaceuticals, Inc.(ALSE)

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Diagnostic & Testing Substances Manufacturers

	1st Jan change	Capi.
DAAN GENE CO., LTD.	-21.18%	1.48B
GENEREACH BIOTECHNOLOGY CORP.	-17.49%	57.39M

Diagnostic & Testing Substances Manufacturers